Differences

This shows you the differences between two versions of the page.

--- coalition_for_epidemic_preparedness_innovations [2022/10/22 01:31]
liam [Portfolio]
+++ coalition_for_epidemic_preparedness_innovations [2024/03/14 01:56] (current)
liam [External links]
@@ Line 116: / Line 116: @@
 CEPI has also received support from private sector entities as well as public contributions through the [[United Nations Foundation]]'s [[COVID-19 Solidarity Response Fund]].
+As of July 2022, CEPI has received $2.3 billion USD from governments and $282.35 million from private investors, for a total of $2.6 billion. An additional $1.28 billion has been pledged for future donation.
+^  Private investors((//Investment Overview.// (2022). CEPI. https://web.archive.org/web/20220829190949/https://cepi.net/wp-content/uploads/2022/02/2022_07_06-CEPI-Investment-Overview.pdf))  ^^^
+^ Name  ^ Contributions (USD)  ^ Pledges (USD)  ^
+| [[Avast]]  | $8,000,000  | -  |
+| [[Bill & Melinda Gates Foundation]]  | $121,400,000  | $154,000,000  |
+| [[Fidelity]]  | $1,490,000  | -  |
+| [[Goldman Sachs]]  | $1,630,000  | -  |
+| [[Nestlé]]  | $1,040,000  | -  |
+| [[Sumitomo Mitsui Banking Corporation]]  | $1,140,000  | -  |
+| [[Paul G. Allen Family Foundation]]  | $3,500,000  | -  |
+| [[COVID-19 Solidarity Response Fund]]  | $10,000,000  | -  |
+| [[Wellcome Trust]]  | $130,900,000  | $150,000,000  |
+| Others (less than $1 million)  | $3,240,000  | -  |
 ===== Activities =====
@@ Line 130: / Line 145: @@
 | [[pharmaceutical_companies:SK Bioscience]] | [[COVID-19]]  | Up to $210 million USD  | [[Recombinant protein]] (approved for use in [[South Korea]])  |
 | [[pharmaceutical_companies:Codiak Biosciences]]  | Broadly Protective Coronavirus Vaccine  | Up to $2.5 million USD  | [[exoVACC]] platform (preclinical)  |
-| [[Centre for Process Innovation]] (CPI), [[California Institute of Technology]], [[University of Oxford]], [[pharmaceutical_companies:Ingenza]]. | Broadly Protective Coronavirus Vaccine  | Up to $30 million USD  | [[Mosaic-8]] nanoparticle (preclinical) |
+| [[Centre for Process Innovation]] (CPI), [[California Institute of Technology]], [[University of Oxford]], [[pharmaceutical_companies:Ingenza]] | Broadly Protective Coronavirus Vaccine  | Up to $30 million USD  | [[Mosaic-8]] nanoparticle (preclinical) |
 | [[pharmaceutical_companies:Bharat Biotech]], [[University of Sydney]], [[pharmaceutical_companies:ExcellGene]]  | Broadly Protective Coronavirus Vaccine  | Up to $12.5 million USD  | Modified trimeric spike (preclinical)  |
 | [[pharmaceutical_companies:MigVax]]  | Broadly Protective Coronavirus Vaccine  | Up to $4.3 million USD  | Subunit vaccine tablet (preclinical)  |
@@ Line 157: / Line 172: @@
 | Inovio Pharmaceuticals  | MERS coronavirus  | -  | Nucleic acid (Phase 2)  |
 | [[pharmaceutical_companies:CureVac]]  | COVID-19  | Up to $15.3 million USD  | Nucleic acid (development discontinued)  |
+| CureVac  | Lassa virus  | Up to $34 million USD  | Nucleic acid (preclinical)  |
+| [[pharmaceutical_companies:Public Health Vaccines]]  | Nipah virus  | Up to $43.6 million USD  | Recombinant [[viral vector]] (Phase 1)  |
+| [[pharmaceutical_companies:Valneva]]  | Chikungunya  | Up to $23.4 million USD  | Live attenuated vaccine (Phase 3)  |
+| [[Colorado State University]]  | [[Rift Valley Fever]]  | Up to $9.5 million USD  | Live attenuated vaccine (preclinical)  |
+| [[pharmaceutical_companies:Emergent BioSolutions]], [[PATH]]  | Lassa virus  | Up to $36 million USD  | Recombinant viral vector (Phase 1)  |
+| [[Wageningen Bioveterinary Research]]  | Rift Valley Fever  | Up to $12.5 million USD  | Live attenuated vaccine (preclinical)  |
+| [[University of Tokyo]]  | Nipah virus  | Up to $31 million USD  | Recombinant viral vector (preclinical)  |
+| [[International AIDS Vaccine Initiative]] (IAVI)  | Lassa virus  | Up to $64.4 million USD  | Recombinant viral vector (Phase 1)  |
+| Themis Bioscience  | Lassa virus  | Up to $37.5 million USD (joint funding with Themis' MERS vaccine)  | Recombinant viral vector (Phase 1)  |
+| Themis Bioscience  | MERS coronavirus  | -  | Recombinant viral vector (preclinical)  |
+| Themis Bioscience  | Chikungunya  | Up to $21 million USD  | Recombinant viral vector (preparing for Phase 3)  |
+| [[pharmaceutical_companies:IDT Biologika]]  | MERS coronavirus  | Up to $36 million USD  | Recombinant viral vector (preclinical)  |
+| [[pharmaceutical_companies:Janssen]], [[University of Oxford]]  | Lassa virus  | Up to $19 million USD for Janssen's Lassa, MERS, Nipah vaccines  | Recombinant viral vector (preclinical)  |
+| Janssen, University of Oxford  | MERS coronavirus  | -  | Recombinant viral vector (preclinical)  |
+| Janssen, University of Oxford  | Nipah virus  | -  | Recombinant viral vector (preclinical)  |
+| [[Imperial College London]]  | [[Marburg virus]]  | Up to $8.4 million USD  | Nucleic acid (preclinical)  |
 ===== External links =====
   * [[https://en.wikipedia.org/wiki/Coalition_for_Epidemic_Preparedness_Innovations|Wikipedia]]
+  * [[https://wiki.whiteroseintelligence.com/Coalition-for-Epidemic-Preparedness-Innovations|White Rose Wiki]]
   * [[https://wikispooks.com/wiki/Coalition_for_Epidemic_Preparedness_Innovations|Wikispooks]]